A First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GLPG3970 Single and Multiple Ascending Doses in Adult Healthy Male Subjects, and in Psoriasis Subjects When Administered Daily for 6 Weeks
Latest Information Update: 16 Jul 2021
At a glance
- Drugs GLPG 3970 (Primary)
- Indications Plaque psoriasis; Psoriasis
- Focus Adverse reactions; First in man
- Acronyms CALOSOMA
- Sponsors Galapagos NV
- 14 Jul 2021 Results published in the Galapagos NV Media Release
- 24 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Jan 2021 Planned End Date changed from 1 Apr 2021 to 1 Mar 2021.